Category Archives: IPASnews
The Bowie Medal recognises research excellence in the field of mass spectrometry by an Australian or New Zealand researcher under the age of 45 years.
Professor John Bowie is a Professor of organic chemistry at the University of Adelaide, with a specialist interest in mass spectrometry and was appointed a Member of the Order of Australia for his contributions to the field.
Tara will be presenting her findings at a keynote lecture at the 26th ANZSMS conference that will be held in Adelaide, 16-20th July.
The award is in recognition of Andre and team’s pioneering research into the development of techniques for extremely precise and accurate measurement of time. Specifically, the Cryogenic Sapphire Clock is a ultra precise oscillator that can measure time at the femtosecond scale (one quadrillionth of a second) and a single second deviation occurs one every 40 million years. This kind of precision is essential for technologies such as metrology and radar.
Weng’s project is titled “Synthesis of low noise microwaves using solitons locked to an ultra-stable cavity” and he will be conducting his research at the École Polytechnique Fédérale de Lausanne (EPFL) in Lausanne, Switzerland. Set on the banks of Lake Geneva, EPFL specialises in physical sciences and was ranked 14th in the world across all fields in QS World University Rankings (2015/2016).
The MSCA Fellowship is awarded to the best and most promising researchers from anywhere in the world. The fellowship funds travel, living costs and employment in an European Union country to facilitate career development, such as research-related and transferable skills, research impact, enhanced cooperation and network building.
Research led by the University of Adelaide is paving the way for safer and more effective drugs to treat type 2 diabetes, reducing side effects and the need for insulin injections.
Two studies, published in the Journal of Medicinal Chemistry and BBA-General Subjects, have shown for the first time how new potential anti-diabetic drugs interact with their target in the body at the molecular level.
These new potential drugs have a completely different action than the most commonly prescribed anti-diabetic, Metformin, which acts on the liver to reduce glucose production, and are potentially more efficient at reducing blood sugar. They target a protein receptor known as PPARgamma found in fat tissue throughout the body, either fully or partially activating it in order to lower blood sugar by increasing sensitivity to insulin and changing the metabolism of fat and sugar.
“Type two diabetes is characterised by resistance to insulin with subsequent high blood sugar which leads to serious disease. It is usually associated with poor lifestyle factors such as diet and lack of exercise,” says lead researcher Dr John Bruning, with the University’s School of Biological Sciences and Institute for Photonics and Advanced Sensing.
“Prevalence of type 2 diabetes in Australia alone has more than tripled since 1990, with an estimated cost of $6 billion a year. The development of safe and more efficient therapeutics is therefore becoming increasingly important.
“People with severe diabetes need to take insulin but having to inject this can be problematic, and it’s difficult to get insulin levels just right. It’s highly desirable for people to come off insulin injections and instead use oral therapeutics.”
The first study, in collaboration with The Scripps Research Institute in Florida, US, describes an honours research project by Rebecca Frkic, where 14 different versions of a drug which partially activates PPARgamma were produced. Partial activation can have the benefit of fewer side-effects than full activation.
The original drug, INT131, is currently being tested in clinical trials in the US but some of the versions produced at the University of Adelaide have increased potency compared to the original, with the potential to further improve the treatment of type 2 diabetes.
“A major finding of this study was being able to show which regions of the drug are most important for interacting with the PPARgamma receptor,” says Dr Bruning. “This means we now have the information to design modified drugs which will work even more efficiently.”
The second study, in collaboration with Flinders University, used X-ray crystallography to demonstrate for the first time exactly how a potential new drug, rivoglitazone, binds with the PPARgamma receptor. Rivoglitazone fully activates PPARgamma but has less side effects than others with this mode of action.
“Showing how this compound interacts with its target is a key step towards being able to design new therapeutics with higher efficiencies and less side-effects,” says lead author Dr Rajapaksha, from Flinders University School of Medicine (now at La Trobe University). “Lack of structural information was hampering determination of the precise mechanisms involved.”
Reference: Frkic et al (2017) “Structure-Activity Relationship of 2,4-dichloro-N-(3,5-dichloro-4-(quinolin-3-yloxy)phenyl)benzenesulfonamide (INT131) Analogs for PPARγ-Targeted Antidiabetics” Journal of Medicinal Chemistry, doi: 10.1021/acs.jmedchem.6b01727.
Rajapaksha et al (2017) “X-ray Crystal Structure of Rivoglitazone bound to PPARγ and PPAR Subtype Selectivity of TZDs” Biochimica et Biophysica Acta (BBA) – General Subjects, doi:10.1016/j.bbagen.2017.05.008.
The Sapphire Clock is a cryogenic sapphire oscillator that allows time to be measured to the femtosecond scale (one quadrillionth of a second) and a single second gained or lost every 40 million year. This kind of accuracy is required for ultra high precision measurements; such as radar technology used at JORN.
Trajan Scientific and Medical (Trajan) has been named one of the top 20 leading “Businesses of Tomorrow” in Australia.
Commissioned by Westpac and conducted by Deloitte, the Businesses of Tomorrow study identified companies that are shaping Australia’s future. Judging criteria included: track record of delivery, ability to meet future challenges and contribution to the community, industry or economy.
Trajan‘s strong collaborative relationship with researchers, such as IPAS within the University of Adelaide, allowing the company to be at the forefront of innovation, was a contributing factor in gaining a place in the top 20 list. Furthermore, Trajan’s evolution from an engineering business to market-focused company allows Trajan to “remain agile and adaptable to market needs”.
A branch of Trajan has been colocated with IPAS since September 2016, following the Photonics Catalyst Program, a joint initiative between the South Australian government and IPAS to connect industry with research.
A full report on the top 200 Australian Businesses of Tomorrow can be found here.
Tim Nelson will be commencing his position as the IPAS Project Manager on 24th April.
Tim’s background is in biomedical engineering and he previously worked at The Bionics Institute in Melbourne, developing and trialling novel implantable devices and strategies for the prediction and treatment of seizures in patients with chronic epilepsy. As an engineering professional, this also incorporated aspects of intellectual property identification and commercialisation strategy development. He studied post-graduate Management at Melbourne Business School prior to taking up a role with Save the Children (Vanuatu) in the development and humanitarian space. As Director of Operations, he was responsible for a large-scale humanitarian program over a 10-month period following Cyclone Pam.
Most recently, Tim worked in the Research & Business Partnerships branch of the University of Adelaide as an industry-engagement specialist, with an interest in innovation, entrepreneurship and tech-transfer.
Prof Andre Luiten has been appointment membership of the National Committee for Physics (NCP), with tenure until 31st March 2020. The NCP is one of 22 national committees within the Australian Academy of Science(AAS), with the broad aim of fostering links between domestic and international scientists within disciplines to the academy.
The University of Adelaide will develop novel very high temperature sensors for global industrial giant Mitsubishi Heavy Industries, the University announced today.
Mitsubishi Heavy Industries and the University have signed contracts for collaborative research by the University’s Institute for Photonics and Advanced Sensing (IPAS) to develop unique optical fibre based ultra-high, multipoint temperature sensors that will enhance the efficiency of their power generation systems.
IPAS and the University’s School of Physical Sciences are renowned for the development of light-based technologies, including optical fibre sensors, for a range of biomedical, defence, environmental and industrial sensing.
“Mitsubishi came to Adelaide looking for global research partners and decided our ultra-high temperature optical fibre sensors would provide a unique opportunity to better understand and improve their world leading power generation systems,” says Professor Mike Brooks, Acting Vice-Chancellor and President at the University of Adelaide.
“The University of Adelaide is honoured to be working with such a giant of industrial engineering and manufacturing as Mitsubishi Heavy Industries.”
Last year IPAS worked with 68 different local and international companies to develop novel breakthrough technologies to help them improve manufacturing and business processes.
“Application of IPAS technologies to date has been largely focused on local South Australian companies – helping them grow their business and retain jobs,” says Professor Andre Luiten, Director of IPAS.
“This new collaboration represents international recognition for the quality of the research and development we are doing, and the difference these emerging disruptive technologies like photonics can make to businesses’ bottom lines.”
“This new collaboration surely brings new technology to sensing of the hot parts of the product of MHI. This will lead to improvements in our product power, and a new business opportunity,” says Dr Fukagawa, the general manager of the heat transfer research department, from Mitsubishi Heavy Industries.
The Mitsubishi contract will build on the technology that IPAS developed with SJ Cheesman for deployment at the Nyrstar Polymetalic Smelter at Port Pirie. This provided novel temperature sensors that can withstand furnace temperatures, enabling processes within the environment of the smelter to be monitored for the first time enabling increased efficiency and significant reductions in energy use
Professor Heike Ebendorff-Heidepriem represented the ARC Centre of Excellence for Nanoscale BioPhotonics and IPAS at Science Meets Parliament, held in Canberra on 21-22nd March 2017.
Science Meets Parliament is an annual event run by Science and Technology Australia and provides ~200 scientists with the opportunity to meet with federal politicians, advisors and policy makers.
Heike had the opportunity to meet with Senator Chris Back, Chair of Foreign Affairs, Defence and Trade Legislative Committee, and Senator Chris Ketter; discussing her research involving the use of optical fibres to create windows into the body, specifically in regards to pain detection.
In addition, Heike also had the opportunity to talk with the Honourable Richard Marles, Shadow Minister for Defence, during the official dinner.
A summary of Science Meets Parliament can be found here.